AMS at a Glance
Advanced Medical Solutions Group plc is a leading developer and manufacturer of innovative and technologically advanced products for the global surgical, woundcare and wound closure markets. Our strategy is based around:
- Growth - Expanding our global presence
- Innovation - Designing and developing leading products
- Value - Offering cost-effective product solutions
Full Year End31 December 2016
Interim Dividend Payment28 October 2016
Half Year Results14 September 2016
Trading Update5 July 2016
Half Year End30 June 2016
Final Dividend Payment10 June 2016
AGM2 June 2016
Advanced Medical Solutions Group plc is pleased to announce they have been awarded the Partnership with the NHS award at the Medilink North West... Read More
Latest Financial Highlights
Financially, we remain very strong. In the first six months of the year, revenue increased by 20% to £39.2 million (2015 H1: £32.7 million), representing growth of 17% at constant currency and adjusted profit before tax increased by 16% to £9.5 million (2015 H1: £8.2 million). Our net cash position has increased to £41.1 million as at 30 June 2016 (31 December 2015: £34.2 million).
One of our key products, LiquiBand®, increased market share to 19% in the US tissue adhesive market and separately, in the US, following FDA approval in November 2015, we are now pleased to have initiated our first sales of RESORBA® sutures into this important market.
During the period we also launched two new ranges of foam dressings. Our antimicrobial foam dressing was launched into Europe following the CE mark approval that we received in August 2015. This foam incorporates PHMB (polyhexamethylene biguanide), which has been shown to be effective against several bacteria and known hospital “super bugs”, strengthening our position in the antimicrobial advanced woundcare market. In addition, our foam portfolio was further increased by the launch of our new atraumatic silicone foam dressing range.
To further accelerate our growth beyond our own strong organic means, we continue to evaluate and consider potential acquisitions that are in line with the Group’s strategy.